

# **Lipophilicity in Drug Action and Toxicology**

edited by  
Vladimir Pliška  
Bernard Testa  
Han van de Waterbeemd



Weinheim · New York · Basel · Cambridge · Tokyo

This Page Intentionally Left Blank

# **Lipophilicity in Drug Action and Toxicology**

edited by Vladimir Pliška, Bernard Testa and  
Han van de Waterbeemd



# **Methods and Principles in Medicinal Chemistry**

Edited by  
R. Mannhold  
H. Kubinyi  
H. Timmerman

## **Editorial Board**

F. Darvas, T. Fujita, C. R. Ganellin,  
F. Gualtieri, U. Hacksell, H.-D. Höltje,  
G. Leclerc, R. Rekker, J.-K. Seydel,  
D. Triggle, H. van de Waterbeemd

# **Lipophilicity in Drug Action and Toxicology**

edited by  
Vladimir Pliška  
Bernard Testa  
Han van de Waterbeemd



Weinheim · New York · Basel · Cambridge · Tokyo

Series Editors:

Prof. Dr. Raimund Mannhold  
Biomedical Research Center  
Molecular Drug Research Group  
Heinrich-Heine-Universität  
Universitätsstraße 1  
D-40225 Düsseldorf  
Germany

Prof. Dr. Hugo Kubinyi  
ZHV/W, A 30  
BASF AG  
D-67056 Ludwigshafen  
Germany

Prof. Dr. Hendrik Timmerman  
Faculty of Chemistry  
Dept. of Pharmacochimistry  
Free University of Amsterdam  
De Boelelaan 1083  
NL-1081 HV Amsterdam  
The Netherlands

Volume editors:

Prof. Dr. Vladimir Pliška  
Department of Animal Science  
Swiss Federal Institute of  
Technology – ETH Zürich  
Tannenstr. 1  
CH-8092 Zürich  
Switzerland

Prof. Dr. Bernard Testa  
University of Lausanne  
School of Pharmacy  
CH-1005 Lausanne  
Switzerland

Priv.-Doz. Dr. Han van de Waterbeemd  
Hoffman-La Roche Ltd.  
Pharma Research New Technologies  
CH-4002 Basel  
Switzerland

This book was carefully produced. Nevertheless, authors, editors and publisher do not warrant the information contained therein to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Published jointly by

VCH Verlagsgesellschaft mbH, Weinheim (Federal Republic of Germany)

VCH Publishers, Inc., New York NY (USA)

Editorial Director: Dr. Michael Bär

Production Manager: Dipl.-Wirt.-Ing. (FH) Bernd Riedel

Library of Congress Card No. applied for.

British Library Cataloguing-in-Publication Data: A catalogue record for this book is available from the British Library.

Deutsche Bibliothek Cataloguing-in-Publication Data:

**Lipophilicity in drug action and toxicology** / ed. by Vladimir

Pliška ... – Weinheim ; New York ; Basel ; Cambridge ; Tokyo : VCH, 1996

(Methods and principles in medicinal chemistry ; Vol. 4)

ISBN 3-527-29383-3

NE: Pliška, Vladimir [Hrsg.]; GT

© VCH Verlagsgesellschaft mbH. D-69451 Weinheim (Federal Republic of Germany), 1996

Printed on acid-free and chlorine-free paper.

All rights reserved (including those of translation in other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Composition: Mitterweger Werksatz GmbH, D-68723 Plankstadt

Printing: Strauss Offsetdruck GmbH, D-69509 Mörlenbach

Bookbinding: Wilh. Osswald + Co, D-67433 Neustadt/Weinstr.

Printed in the Federal Republic of Germany.

Distribution:

VCH, P.O. Box 10 11 61, D-69451 Weinheim (Federal Republic of Germany)

Switzerland: VCH, P.O. Box, CH-4020 Basel (Switzerland)

United Kingdom and Ireland: VCH (UK) Ltd., 8 Wellington Court, Cambridge CB1 1HZ (England)

USA and Canada: VCH, 220 East 23rd Street, New York, NY 10010-4606 (USA)

Japan: VCH, Eikow Building, 10-9 Hongo 1-chome, Bunkyo-ku, Tokyo 113 (Japan)

# Preface

After three volumes covering the various techniques quantifying the relations of biological activity and chemical properties of drug molecules, the fourth volume in the series "Methods and Principles in Medicinal Chemistry" focuses on the role of lipophilicity in drug action and toxicology.

Lipophilicity is well known as a prime physico-chemical descriptor of xenobiotics with relevance to their biological properties. The hydrophobic interactions of drugs with their receptors, the pharmacokinetic behaviour of drug molecules, toxicological properties and pharmaceutical aspects like solubility are examples of a steadily increasing number of topics in which lipophilicity plays an important role.

In keeping with the outstanding importance of lipophilicity in biosciences, this topic is treated in the present volume by more than twenty leading experts. The first out of five sections covers the physico-chemical background of molecular interactions and partitioning. The following two sections deal with the various experimental and computational approaches to quantifying lipophilicity. Experimental assessment includes partitioning as well as chromatographic alternatives. Computational procedures range from the classical approach employing hydrophobic fragmental constants to three-dimensional concepts which reflect the impact of conformational aspects of lipophilic behaviour. The last two sections reflect the relevance of lipophilicity in biological responses to xenobiotics and in drug design. Inter alia, the dependence of pharmacokinetic processes, like membrane transport and biotransformation on lipophilicity as well as environmental hazard assessment using lipophilicity data, deserve mention here. Lipophilicity scales for peptides and amino acids are discussed in their relation to drug design.

The present volume convincingly achieves its main objective, to put emphasis on lipophilicity as an important property for a vast number of biological processes.

December 1995

Düsseldorf  
Ludwigshafen  
Amsterdam

Raimund Mannhold  
Hugo Kubinyi  
Hendrik Timmerman

# Methods and Principles in Medicinal Chemistry

Edited by  
R. Mannhold  
H. Kubinyi  
H. Timmerman

## **Volume 1**

Hugo Kubinyi

*QSAR: Hansch Analysis and Related Approaches*

## **Volume 2**

Han van de Waterbeemd (ed.)

*Chemometric Methods in Molecular Design*

## **Volume 3**

Han van de Waterbeemd (ed.)

*Advanced Computer-Assisted Techniques in Drug Discovery*

## **Volume 4**

Vladimir Pliška, Bernard Testa, Han van de Waterbeemd (eds.)

*Lipophilicity in Drug Action and Toxicology*

## **Volume 5**

Hans-Dieter Höltje, Gert Folkers

*Molecular Modeling*



## A Personal Foreword

The idea to write a state-of-the-art monograph examining manifold aspects of lipophilicity was born at the 7th European QSAR Symposium in Interlaken (1988). The Organizing Committee suggested that the spared funds of the Symposium be utilized for organizing a workshop on lipophilicity which would establish a solid base for such a monograph, and challenged us to undertake the task. It took us six long years to fulfill the first part of our commitment. The *Symposium on Lipophilicity in Drug Research and Toxicology* was held in Lausanne in March 1995, and was only possible thanks to an additional support by numerous companies and organizations. The remaining task turned out to be even more difficult. To publish a book *so* specified meant to ask a number of authors for collaboration. The our great joy, the majority of the contacted persons accepted, wrote their chapters, and even delivered their manuscript in time. We thank them for their collaboration.

However, editing is a thankless task. The text of any book of this series should be generally comprehensible, thus assuming a more or less consistent style. In trying this, editors are put under pressure by both authors and publisher, for different reasons. On top of it, there are also series editors who have firm and generally justified notion about the style of the entire book series. There is also a different degree of bias by individual partners: in our estimate the highest one with the authors, who usually present their favorite child with a great deal of an understandable enthusiasm, and the lowest one with the publishers who ist obliged to consider – and to foresee – the general success of the publication. Editors and series editors may find themselves somewhere half-way in between. Provided that the final outcome does *not* have a character of conference proceedings, the editors are compelled to set up basic style rules, and to exercise a certain pressure on the authors to follow them. In most instances, this was benevolently understood and respected.

The book contains, besides purely methodological contributions and established physico-chemical concepts, also chapters which my seemingly touch the problem of lipophilicity only from afar, or which may rather be considered as dreams of the future. However, we are convinced that they have a rightful place in this book.

There are many persons, in additions to the participating authors, to whom we owe our thanks. To name only very few of them, Professor Jean-Luc Fauchère gave the spiritual, and also material, impulse to this book. The VCH editors, Dr. Thomas Mager and Dr. Michael Bär carried out all the burdens asociated with the preparation for printing and manufacturing. And our colleagues, the series editors Professors Raimund Mannhold, Hugo Kubinyi, and Hendrik Timmerman, were most helpful with their critical comments.

February 1996

Zürich  
Lausanne  
Basel

Vladimir Pliška  
Bernard Testa  
Han van de Waterbeemd

This Page Intentionally Left Blank

# List of Contributors

Michael H. Abraham  
The Department of Chemistry  
University College London  
20 Gordon Street  
London WC1H 0AJ  
UK

Philip S. Burton  
Drug Delivery Research Systems  
Upjohn Laboratories  
Kalamazoo, MI  
USA

Alex Avdeef  
Sirius Analytical Instruments Ltd.  
Riverside  
Forest Row Business Park  
Forest Row  
East Sussex RH18 5DW  
UK

Pierre-Alain Carrupt  
Institut de Chimie Thérapeutique  
BEP  
Université de Lausanne  
CH-1015 Lausanne-Dorigny  
Switzerland

Štefan Baláz  
Department of Biochemical Technology  
Slovak Technical University  
Radlinského 9  
SK-81237 Bratislava  
Slovakia

Harpreet S. Chadha  
The Department of Chemistry  
University College London  
20 Gordon Street  
London WC1H 0AJ  
UK

Frédéric Billois  
Institut de Chimie Thérapeutique  
BEP  
Université de Lausanne  
CH-1015 Lausanne-Dorigny  
Switzerland

Marvin Charton  
Chemistry Department  
Pratt Institute  
Brooklyn, NY 11205  
USA

Ronald T. Borchardt  
Pharmaceutical Chemistry Department  
University of Kansas  
Lawrence, KS  
USA

Chao-Kun Cheng  
Department of Mathematical Sciences  
Virginia Commonwealth University  
Richmond, VA  
USA

Robert A. Conradi  
Drug Delivery Research Systems  
Upjohn laboratories  
Kalamazoo, MI  
USA

Karl Dross  
C. and O. Vogt Institute for Brain Research  
Heinrich-Heine-Universität  
Universitätstrasse 1  
40225 Düsseldorf  
Germany

Emanuel Escher  
Département de Pharmacologie  
Faculté de Médecine  
Université de Sherbrooke  
Sherbrooke (Quebec)  
J1H 5N4  
Canada

Jean-Luc Fauchère  
Institut de Recherches SERVIER  
11 rue des Moulineaux  
92150 Suresnes  
France

Holger Fischer  
F. Hoffmann-La Roche Ltd.  
Pharma Research New Technologies  
Structure-Property Correlations Group  
CH-4002 Basel  
Switzerland

Gerd Folkers  
Department of Pharmacy  
ETH Zürich  
Winterthurerstrasse 190  
CH-8057 Zürich  
Switzerland

Patrick Guillard  
Institut de Chimie thérapeutique  
BEP  
Université de Lausanne  
CH-1015 Lausanne-Dorigny  
Switzerland

Pavel Hobza  
J. Heyrovský Institute of Physical  
Chemistry  
Academy of Sciences of the Czech Republic  
Dolejškova 3  
182 23 Prague 8  
Czech Republic

Manfred Kansy  
F. Hoffmann-La Roche Ltd.  
Pharma Research New Technologies  
Structure-Property Correlations Group  
CH-4002 Basel  
Switzerland

Lemont B. Kier  
Department of Medicinal Chemistry  
Virginia Commonwealth University  
Richmond, VA  
USA

Albert J. Leo  
Pomona College and BioByte Corporation  
Claremont  
California, CA 91711-0517  
USA

Robert L. Lipnick  
Office of Pollution Prevention and Toxics  
U.S. Environmental Protection Agency  
Washington, DC 20460  
USA

Giuseppe Lisa  
Institut de Chimie Thérapeutique  
BEP  
Université de Lausanne  
CH-1015 Lausanne-Dorigny  
Switzerland

Raimund Mannhold  
Department of Laser Medicine  
Molecular Drug Research Group  
Heinrich-Heine-Universität  
Universitätstrasse 1  
D-40225 Düsseldorf  
Germany

Alfred Merz  
Department of Pharmacy  
ETH Zürich  
Winterthurerstrasse 190  
CH-8057 Zürich  
Switzerland

Christophe Meyer  
Institut National de la Recherche Agro-  
nomique  
BP 527  
F-44026 Nantes Cedex  
France

Serge Pérez  
Institut National de la Recherche Agro-  
nomique  
BP 527  
F-44026 Nantes Cedex  
France

Vladimir Pliška  
Department of Animal Science  
Swiss Federal Institute of Technology  
ETH Zürich  
CH-8092 Zürich  
Switzerland

W. Graham Richards  
Physical and Theoretical Chemistry  
Oxford University  
Oxford  
UK

Christoph Sonntag  
C. and O. Vogt Institute for Brain Re-  
search  
Heinrich-Heine-Universität  
Universitätstrasse 1  
D-40225 Düsseldorf  
Germany

Albert Taylor  
Servier Research and Development  
Fulmer Hall  
Windmill Road  
Fulmer  
Slough SL3 6HH  
UK

Bernard Testa  
Institut de Chimie Thérapeutique  
BEP  
Université de Lausanne  
CH-1015 Lausanne-Dorigny  
Switzerland

Ruey-Shiuan Tsai  
Institut de Chimie Thérapeutique  
BEP  
Université de Lausanne  
CH-1015 Lausanne-Dorigny  
Switzerland

Michael S. Tute  
Chemistry Department  
University of Kent at Canterbury  
Canterbury  
Kent  
UK

Peter Vis  
Servier Research and Development  
Fulmer Hall  
Windmill Road  
Fulmer  
Slough SL3 6HH  
UK

Björn Wagner  
F. Hoffmann-La Roche Ltd.  
Pharma Research New Technologies  
Structure-Property Correlations Group  
CH-4002 Basel  
Switzerland

Bernard Walther  
Servier Research and Development  
Fulmer Hall  
Windmill Road  
Fulmer  
Slough SL3 6HH  
UK

Han van de Waterbeemd  
F. Hoffmann-La Roche Ltd.  
Pharma Research New Technologies  
Structure-Property Correlations Group  
CH-4002 Basel  
Switzerland

Peter Weber  
Institut de Chimie Thérapeutique  
BEP  
Université de Lausanne  
CH-1015 Lausanne-Dorigny  
Switzerland

Rudolf Zahradník  
J. Heyrovský Institute of Physical  
Chemistry  
Academy of Sciences of the Czech Re-  
public  
Dolejšková 3  
182 23 Prague 8  
Czech Republic

# Contents

<b>Preface</b>	V
<b>A Personal Foreword</b>	VII
<b>List of Contributors</b>	IX
<b>1 Lipophilicity: The Empirical Tool and the Fundamental Objective. An Introduction</b>	1
<i>V. Pliška, B. Testa and H. Van de Waterbeemd</i>	
1.1 Setting the Scene	1
1.2 Biological Aspects	1
1.3 The Molecule in the Background	2
1.4 Some Pragmatic Aspects	3
1.4.1 Definitions and Symbols	3
1.4.2 Experimental Techniques	4
1.4.3 Computational Procedures	5
1.5 Objectives of the Book	5
References	6
<b>2 Lipophilicity: A History</b>	7
<i>M. S. Tute</i>	
2.1 Introduction	7
2.2 Measurement of Lipophilicity	9
2.3 Calculation of Lipophilicity	11
2.3.1 Substitution Method	11
2.3.2 Fragment Additivity Method	12
2.3.3 Fragmentation into Atoms	13
2.3.4 Molecular Orbital Calculations	14
2.3.5 Calculations Based on Surface Area	14
2.4 The Nature of Lipophilicity	17
2.4.1 Relation to Other Molecular Properties	18
2.4.2 Thermodynamics of Partitioning	19
2.4.2.1 Phase Transfer	19
2.4.2.2 The Aqueous Phase and the "Hydrophobic Bond"	21
2.5 Lipophilicity and Biological Activity	22
References	24

<b>3</b>	<b>Thermodynamics of van der Waals and Hydrophobic Interactions</b> . . . . .	<b>27</b>
	<i>R. Zahradník and P. Hobza</i>	
3.1	Introduction . . . . .	28
3.2	Outline of Thermodynamics and Auxiliary Disciplines . . . . .	31
3.3	Intermolecular Interactions of the van der Waals Type . . . . .	33
3.3.1	The Physical Nature of van der Waals Interactions . . . . .	33
3.3.2	Classification of van der Waals Clusters . . . . .	34
3.3.3	Calculation of the Interaction Energy . . . . .	34
3.3.3.1	Nonempirical <i>ab initio</i> Variational Method . . . . .	35
3.3.3.2	Density Functional Theory . . . . .	36
3.3.3.3	Semiempirical Methods . . . . .	36
3.3.3.4	Empirical Procedures . . . . .	36
3.3.4	How to Obtain a Consistent Set of Various Calculated Properties for van der Waals Clusters . . . . .	37
3.3.4.1	Potential Energy Surface (P. E. S.) . . . . .	37
3.3.4.2	Stabilization Energy . . . . .	37
3.3.4.3	Empirical Potential . . . . .	38
3.3.4.4	Vibration Frequencies . . . . .	38
3.3.4.5	Computer Experiments . . . . .	38
3.4	Processes Involving Hydrophobic Effects . . . . .	38
3.5	Specific Illustrations . . . . .	40
3.5.1	<i>Ab initio</i> Evaluation of a Consistent Set of Various Properties of the Benzene . . . Ar <sub>n</sub> Cluster . . . . .	40
3.5.1.1	Potential Energy Surface . . . . .	40
3.5.1.2	More Accurate Calculations for the Global Minimum . . . . .	41
3.5.1.3	Preparation of the Empirical Potential . . . . .	41
3.5.1.4	Vibrational Frequencies . . . . .	42
3.5.1.5	Molecular Dynamics Simulations . . . . .	42
3.5.2	Monte Carlo Free Energy Perturbation Calculation: Solvation Free Energy of Methanol and Ethane . . . . .	43
	References . . . . .	43
	Appendices . . . . .	45
 <b>4</b>	 <b>Intramolecular Interactions Encoded in Lipophilicity: Their Nature and Significance</b> . . . . .	 <b>49</b>
	<i>B. Testa, P.-A. Carrupt, P. Gaillard and R.-S. Tsai</i>	
4.1.	Introduction: The Concept of Molecular Structure . . . . .	49
4.1.1	The Elementary and Geometric Levels of Description . . . . .	49
4.1.2	The Stereoelectronic Levels of Description . . . . .	50
4.1.3	Social Molecules . . . . .	51
4.2	Intermolecular Forces Encoded in Lipophilicity . . . . .	52
4.2.1	Recognition Forces in Molecular Pharmacology and Biology . . . . .	52
4.2.2	Factorization of Molecular Lipophilicity . . . . .	53



4.2.3	Polar Interactions Encoded in Lipophilicity . . . . .	54
4.2.4	Nonpolar Interactions Encoded in Lipophilicity . . . . .	55
4.2.5	Recognition Forces Encoded in Lipophilicity . . . . .	55
4.3	Intramolecular Interactions Affecting Lipophilicity . . . . .	55
4.3.1	Electronic Conjugations . . . . .	56
4.3.1.1	In Aromatic Systems . . . . .	56
4.3.1.2	Across Aliphatic Segments . . . . .	57
4.3.2	Interactions Involving Polar Groups . . . . .	58
4.3.2.1	Proximity Effects Between Two Neutral Polar Groups . . . . .	58
4.3.2.2	Internal H-bonds . . . . .	59
4.3.2.3	The Case of Zwitterions . . . . .	61
4.3.2.4	Hydrophilic Collapse . . . . .	62
4.3.2.5	Proximity Effects Between Polar and Nonpolar Groups . . . . .	63
4.3.3	Steric/Hydrophobic Effects . . . . .	64
4.3.3.1	Shielding of Polar Groups . . . . .	64
4.3.3.3	Hydrophobic Collapse . . . . .	65
4.4	Structural Factors Influencing Intramolecular Interactions . . . . .	65
4.4.1	Positional Isomerism . . . . .	66
4.4.2	Stereoisomerism . . . . .	67
4.4.3	Ionization . . . . .	67
4.4.4	Molecular Size and Chameleonic Behavior . . . . .	68
4.5	Outlook: Molecular Polymorphism in Drug Design . . . . .	69
	Acknowledgements . . . . .	70
	References . . . . .	70

## 5 Lipophilicity Measurement by Reversed-Phase High Performance Liquid Chromatography (RP-HPLC) . . . . . 73

*H. van de Waterbeemd, M. Kansy, B. Wagner and H. Fischer*

5.1	Historical . . . . .	74
5.2	Principle of Lipophilicity Measurements by RPLC . . . . .	74
5.2.1	Description of the Method . . . . .	74
5.2.2	Log $k$ or log $k_w$ . . . . .	76
5.3	Stationary Phases (Column Packings) . . . . .	77
5.3.1	Overview . . . . .	77
5.3.2	New HPLC Packing Materials for Lipophilicity Measurements . . . . .	78
5.3.3	Column Length . . . . .	78
5.4	Mobiles Phases . . . . .	78
5.4.1	Selection of Organic Modifier . . . . .	78
5.4.2	Buffer and the Effect of Ionization . . . . .	79
5.4.2.1	Buffer . . . . .	79
5.4.2.2	Ionization Correction . . . . .	79
5.4.3	Masking Agents . . . . .	79
5.4.4	Ion Pairs and Ion Pair Chromatography (IPC) . . . . .	80

5.5	Retention Mechanism . . . . .	80
5.5.1	Solvatochromic Analysis . . . . .	80
5.5.2	Slope Analysis and Hydrogen-Bonding Capacity . . . . .	81
5.5.3	Effect of Intercharge Distance in Zwitterions . . . . .	82
5.5.4	Effect of Conformation on Retention . . . . .	82
5.5.5	Lipophilicity of Peptides and Proteins . . . . .	83
5.6	Correlations of $\log k_w$ Values to $\log P_{\text{oct}}$ and Other $\log P$ Scales . . . .	83
5.7	Recommendations . . . . .	85
5.7.1	OECD/EU Guidelines . . . . .	85
5.7.2	Recommended Method . . . . .	85
	Acknowledgements . . . . .	85
	References . . . . .	85
<b>6</b>	<b>Centrifugal Partition Chromatography for Lipophilicity Measurements</b> . . . . .	<b>89</b>
	<i>R.-S. Tsai, G. Lisa, P.-A. Carrupt and B. Testa</i>	
6.1	Introduction: a Need for an Accurate Method for Partition Coefficient Measurements . . . . .	89
6.2	Historical Aspects . . . . .	91
6.2.1	The Discovery and Development of CPC . . . . .	91
6.2.2	From $\log P_{\text{octanol-hexane/water}}$ to $\log P_{\text{oct}}$ Using Multichannel Cartridge-type CPC . . . . .	92
6.2.3	From $\log P_{\text{oct}}$ to $\log P$ (Solvent “quartet”) Using Coil Planet-type CPC . . . . .	92
6.3	Mechanisms of Solute Partitioning in Various Types of CPC . . . . .	93
6.3.1	Hydrostatic Equilibrium Systems . . . . .	93
6.3.2	Hydrodynamic Equilibrium Systems . . . . .	95
6.4	Method Development for $\log P$ Measurements Using CPC . . . . .	96
6.4.1	Calculation of Partition Coefficients . . . . .	96
6.4.2	Considerations About the Equipment (Mainly the Centrifuge) . . . .	96
6.4.3	Experimental Design . . . . .	98
6.5	Validation of $\log P$ Values Obtained from CPC . . . . .	100
6.5.1	Partition Coefficients in <i>n</i> -Octanol/Water Systems . . . . .	101
6.5.2	Partition Coefficients in Alkane/Water Systems . . . . .	101
6.5.3	Partition Coefficients in di- <i>n</i> -Butyl Ether/Water and Chloroform/Water Systems . . . . .	102
6.6	Application to the Determination of Solute Structural Properties . . .	102
6.6.1	The Case of Zwitterionic Amino Acids . . . . .	102
6.6.2	The Case of Anti-Dopaminergic 6-Methoxysalicylamides . . . . .	104
6.7	Advantages and Limitations of the CPC Method for $\log P$ Measurements . . . . .	104
6.8	Concluding Remarks . . . . .	105
	Acknowledgments . . . . .	106
	References . . . . .	106

<b>7</b>	<b>Assessment of Distribution-pH Profiles</b> . . . . .	<b>109</b>
	<i>A. Avdeef</i>	
7.1	Introduction . . . . .	109
7.2	Partition Coefficient, log $P$ , and the Dyrssen Two-Phase Titration . .	110
7.2.1	Historical Background . . . . .	110
7.2.2	Titration . . . . .	110
7.2.3	Bjerrum Difference Plots . . . . .	112
7.2.4	pH Definitions and Electrode Standardization . . . . .	113
7.2.5	Definitions of Constants . . . . .	114
7.3	Distribution Function ( $D$ ) and the Lipophilicity Profile (log $D$ vs pH) . . . . .	115
7.3.1	Experimental Evidence for Ion-Pairing: Shake-Flask vs pH-Metric . . . . .	118
7.3.2	Further Insights into the Scherrer $pK_a$ . . . . .	121
7.3.3	pH Scale in Lipids? . . . . .	122
7.3.4	Monoprotic Substance log $D$ -pH Curve Shape Analysis . . . . .	123
7.3.5	Application of Shape Analysis to One-Point log $D$ Shake-Flask Measurement . . . . .	123
7.3.6	Effect of Salt: Monoprotic Examples . . . . .	126
7.3.7	Debye-Hückel Corrections to Octanol/Water Partition Constants . .	127
7.3.8	Diprotic Substance log $D$ -pH Curve Shape Analysis (12 Cases) . . .	128
7.3.9	Diprotic Molecules with Two Different Ion Pair Partitionings . . . .	129
7.3.10	Macro- $pK_a$ , Micro- $pK_a$ , and Zwitterions . . . . .	131
7.3.11	Relationship between Micro-log $P$ , Macro-log $p$ , and log $D$ . . . . .	132
7.3.12	Micro-log $p$ Application . . . . .	133
7.3.13	Partitioning of the Amino Acids Phenylalanine and Tryptophanylphenylalanine . . . . .	133
7.3.14	Partitioning of Morphine Derivatives and Metabolites . . . . .	135
7.3.15	Drug-Liposome Partitioning, First Look . . . . .	136
7.4	Outlook . . . . .	136
	Acknowledgements . . . . .	137
	References . . . . .	137
<b>8</b>	<b>Estimation of Lipophilicity by Reversed-Phase Thin-Layer Chromatography</b> . . . . .	<b>141</b>
	<i>R. Mannhold, K. Dross and C. Sonntag</i>	
8.1	Introduction . . . . .	141
8.2	Stationary Phase . . . . .	143
8.3	Mobile Phase . . . . .	145
8.3.1	The Influence of the Organic Modifier on $R_M$ . . . . .	145
8.3.2	The Influence of Solvent pH and Ionic Strength on $R_M$ . . . . .	145
8.4	$R_{Mw}$ and Extrapolation Methods . . . . .	146
8.4.1	Quadratic Function . . . . .	147
8.4.2	Exponential Function . . . . .	147

8.4.3	Mixed Exponential/Linear Function . . . . .	148
8.5	Analysis of the $R_M/\varphi$ Relation . . . . .	148
8.6	Comparison with Other Lipophilicity Data . . . . .	149
8.6.1	The Comparison of $R_{Mw}$ with $\log k_w$ . . . . .	149
8.6.2	The Comparison of $R_{Mw}$ with $\log P_{Oct}$ . . . . .	149
8.6.3	The Comparison of $R_{Mw}$ with Calculated $\log P$ . . . . .	152
8.7	Concluding Remarks . . . . .	153
	References . . . . .	154
<b>9</b>	<b>The Future of <math>\log P</math> Calculation</b> . . . . .	<b>157</b>
	<i>A. J. Leo</i>	
9.1	Introduction . . . . .	157
9.2	Methods . . . . .	158
9.2.1	The Substituent Method . . . . .	158
9.2.2	Atom-Based Methods . . . . .	158
9.2.3	Methods Based on Molecular Properties . . . . .	159
9.2.4	Fragment-Based Methods . . . . .	161
9.3	Common Problems . . . . .	161
9.3.1	How is the "True" Structure to be Represented? . . . . .	161
9.3.2	Intramolecular H-bonding . . . . .	165
9.4	Conclusions . . . . .	170
	References . . . . .	171
<b>10</b>	<b>Theoretical Calculation of Partition Coefficients</b> . . . . .	<b>173</b>
	<i>W. G. Richards</i>	
10.1	Introduction . . . . .	173
10.2	Statistical Thermodynamics . . . . .	174
10.3	Equilibrium Constants . . . . .	174
10.4	Free Energy Perturbation Calculations . . . . .	175
10.5	Partition Coefficients . . . . .	176
10.6	Membrane Simulations . . . . .	178
10.7	Future Outlook . . . . .	180
	References . . . . .	180
<b>11</b>	<b>Cellular Automata Model of Partitioning Between Liquid Phases</b> . . . . .	<b>181</b>
	<i>L. B. Kier and C.-K. Cheng</i>	
11.1	Introduction . . . . .	181
11.2	Cellular Automata . . . . .	182
11.2.1	The Model . . . . .	182
11.2.2	The Molecular System . . . . .	183
11.2.3	The Dimensional Relationship in Cellular Automata Models . . . . .	184
11.2.4	The Rules . . . . .	184

11.3	Models of Solution Phenomena . . . . .	185
11.3.1	A Model of Water . . . . .	185
11.3.2	A Model of a Solution . . . . .	186
11.3.3	A Model of the Hydrophobic Effect . . . . .	186
11.3.4	A Model of Dissolution . . . . .	186
11.4	A Cellular Automata Model of Immiscibility . . . . .	187
11.4.1	Immiscible Liquids . . . . .	187
11.4.2	A Model of Immiscible Systems . . . . .	187
11.4.3	An Immiscible Liquid Simulation . . . . .	188
11.5	A Model of Partitioning Between Immiscible Liquids . . . . .	190
11.6	Conclusion . . . . .	192
	Acknowledgements . . . . .	193
	References . . . . .	194
<b>12</b>	<b>The Molecular Lipophilicity Potential (MLP): A New Tool for log <i>P</i> Calculations and Docking and in Comparative Molecular Field Analysis (CoMFA)</b> . . . . .	<b>195</b>
	<i>P.-A. Carrupt, P. Gaillard, F. Billois, P. Weber, B. Testa, C. Meyer and S. Pérez</i>	
12.1	Computational Approaches to Lipophilicity . . . . .	195
12.1.1	Introduction . . . . .	195
12.1.2	Limits of Fragmental Systems . . . . .	196
12.2	The Molecular Lipophilicity Potential (MLP): a Tool to Compute Partition Coefficients from 3D Structures . . . . .	196
12.2.1	Derivation of the MLP . . . . .	196
12.2.2	Back-Calculation of Partition Coefficient . . . . .	197
12.3	The MLP: a Tool to Explore Conformational Effects on Lipophilicity . . . . .	198
12.3.1	Quenched Molecular Dynamics: an Effective Exploration of Conformational Space . . . . .	198
12.3.2	Conformation-Dependent Variations in Lipophilicity as Described by the MLP . . . . .	199
12.3.3	Applications . . . . .	200
12.3.3.1	Lipophilicity Variation in GABA-receptor Antagonists . . . . .	200
12.3.3.2	Lipophilicity of L-Dopa Esters . . . . .	202
12.4	The MLP as a Docking Tool . . . . .	204
12.4.1	Intrinsic MLP, Perceived MLP, and Similarities Between Them . . . .	204
12.4.2	Applications . . . . .	204
12.4.2.1	Binding Modes of some D <sub>2</sub> -receptor Agonists . . . . .	204
12.4.2.2	Binding Modes of HEL (52–61) to the I-A <sup>k</sup> MHC II Protein . . . . .	206
12.5	The MLP as an Additional Field in 3D QSAR . . . . .	208
12.5.1	Limits of Standard CoMFA Approaches . . . . .	208
12.5.2	The MLP, a Third Field in CoMFA . . . . .	209
12.5.2.1	Theory . . . . .	209
12.5.2.2	Intercorrelations of CoMFA Results Obtained with Different Fields . . . . .	210

12.5.3	Applications	211
12.5.3.1	Binding to 5-HT <sub>1A</sub> Receptors	211
12.5.3.2	CoMFA Models of Sweetness in Halogenated Sucroses	213
12.6	Perspectives	214
	Acknowledgements	215
	References	215
	Appendix	217
<b>13</b>	<b>Hydrophobic Fields in Quantitative Structure-Activity Relationships</b>	<b>219</b>
	<i>G. Folkers and A. Merz</i>	
13.1	Introduction	219
13.2	Definition	220
13.3	Fragmental Property Contributions	221
13.4	Algorithms for Calculation of Hydrophobic Fields	222
13.4.1	GRID	222
13.4.2	Molecular Lipophilicity Potential (MLP)	223
13.4.3	Hydrophobic Interaction Potential (HINT)	223
13.5	Combination of Hydrophobic Fields with 3D QSAR Techniques	224
13.6	Mechanistic Interpretation of Protein-Ligand Crystal Data	224
13.7	YAK	225
13.8	Experiments and Caveats	226
13.9	Outlook	230
	References	231
<b>14</b>	<b>Physico-Chemical and Biological Factors that Influence a Drug's Cellular Permeability by Passive Diffusion</b>	<b>233</b>
	<i>R. A. Conradi, P. S. Burton and R. T. Borchardt</i>	
14.1	Introduction	233
14.1.1	Cellular Barriers to Drug Transport	234
14.1.2	Transport Pathways	235
14.1.2.1	Paracellular Transport	235
14.1.2.2	Transcellular Transport	236
14.2	Physico-Chemical Factors Influencing Transcellular Passive Diffusion	237
14.2.1	Predictive Partition Coefficients	240
14.2.2	Relationship to a Drug's Lipophilicity	241
14.2.3	Relationship to a Drug's Hydrogen Bonding Potential	242
14.2.3.1	Intestinal Mucosal Cell Transport	242
14.2.3.2	Blood-Brain Barrier Transport	245
14.2.3.3	Mechanistic Considerations	245
14.2.4	Relationship to a Drug's Solution Conformation	246
14.3	Biological Factors Influencing Transcellular Passive Permeability: Polarized Efflux Systems	247
14.4	Rationally Designing Drugs with Enhanced Cellular Permeability	249
	Acknowledgements	249
	References	250

<b>15</b>	<b>Lipophilicity of Metabolites and Its Role in Biotransformation</b> . . . . .	<b>253</b>
	<i>B. Walther, P. Vis and A. Taylor</i>	
15.1	Introduction . . . . .	253
15.2	Introduction of a Lipophilic Group into a Drug . . . . .	254
15.3	Introduction of a Polar Group into a Drug . . . . .	256
15.3.1	Increase of Lipophilicity Following a Phase 1 Reaction . . . . .	256
15.3.2	Increase of Lipophilicity Following a Phase 2 Reaction . . . . .	257
15.4	Pharmacokinetic and Pharmacodynamic Consequences . . . . .	259
	References . . . . .	261
 <b>16</b>	 <b>The Role of Lipophilicity in Biological Response to Drugs and Endogenous Ligands</b> . . . . .	 <b>263</b>
	<i>V. Pliška</i>	
16.1	Introductory Comments and Definitions . . . . .	265
16.2	Phases of a Biological Response . . . . .	266
16.3	Stimulus-Response Profiles . . . . .	267
16.3.1	Characteristic Types of Response Profiles . . . . .	267
16.3.2	Time and Intensity Components of a Response . . . . .	269
16.4	Bioactive Substance in the Receptor Compartment: Response Function . . . . .	269
16.4.1	General Formula of the Response Function . . . . .	269
16.4.2	Transport and Partitioning . . . . .	270
16.4.3	Compartmentation in the Vicinity of a Membrane . . . . .	271
16.4.4	Partitioning in the Aqueous/Lipid Interphase on Cell Surface . . . . .	272
16.5	Ligand-Receptor Interaction . . . . .	274
16.6	Factors Determining Biological Responses: a Summary . . . . .	277
16.7	Partial Agonism and the Role of Lipophilicity . . . . .	277
16.7.1	Dose-Response Relationship and the Phenomenon of “Partial Agonism” . . . . .	277
16.7.2	Partial Agonism in Cholinergic Systems . . . . .	279
16.7.3	Molecular Perturbation Hypotheses . . . . .	280
16.7.4	“Wrong-Way” Binding Model of Partial Agonism . . . . .	280
16.7.5	Effect of Lipophilicity on Intrinsic Activity . . . . .	281
16.7.6	Other Examples of Full-to-Partial-Agonism Transition due to Lipophilicity Increase . . . . .	282
16.8	Bell-Shaped Dose-Response Curves . . . . .	283
16.9	Thermodynamic Aspects of Variable Intrinsic Activity . . . . .	285
16.9.1	Hydrophobic Interactions as an Entropy-Driven Process . . . . .	285
16.9.2	$\Delta S^\circ$ , $\Delta H^\circ$ Relationships in Some Receptor Systems . . . . .	286
16.9.2.1	Muscarinic Receptors . . . . .	286
16.9.2.2	$\beta$ -Adrenergic Receptors . . . . .	287
16.9.2.3	GABA <sub>A</sub> Receptors . . . . .	289
16.9.2.4	Opioid Receptors . . . . .	289

16.9.2.5	Adenosine A <sub>1</sub> Receptors . . . . .	289
16.9.2.6	Dopamine D <sub>2</sub> Receptors . . . . .	290
16.9.3	Entropy-Enthalpy Compensation . . . . .	290
16.10	Outlook . . . . .	291
	References . . . . .	291
<b>17</b>	<b>Membrane Transport and Cellular Distribution . . . . .</b>	<b>295</b>
	<i>Š. Baláz</i>	
17.1	Introduction . . . . .	296
17.2	Model . . . . .	297
17.2.1	Model Construction . . . . .	297
17.2.2	Relation Between Individual Distribution Processes and Drug Properties . . . . .	298
17.2.2.1	Transport Through Phase Interface . . . . .	298
17.2.2.2	Membrane Accumulation . . . . .	299
17.2.2.3	Binding to Cell Constituents . . . . .	299
17.2.2.4	Enzymatic and Spontaneous Reactions . . . . .	299
17.3	Numerical Simulations . . . . .	300
17.3.1	Closed Systems . . . . .	302
17.3.1.1	Nonequilibrium Period . . . . .	302
17.3.1.2	Equilibrium Period . . . . .	303
17.3.1.3	Mixed Period . . . . .	303
17.3.2	Open Systems . . . . .	303
17.4	Explicit Descriptions . . . . .	304
17.4.1	Nonionizable Compounds . . . . .	305
17.4.2	Ionizable Compounds . . . . .	306
17.4.3	Varying Acidity of the External Medium . . . . .	307
17.5	Outlook . . . . .	307
	Acknowledgements . . . . .	307
	References . . . . .	308
<b>18</b>	<b>Applications of a Solvation Equation to Drug Transport Properties . . . . .</b>	<b>311</b>
	<i>M. H. Abraham and H. S. Chadra</i>	
18.1	Introduction . . . . .	312
18.2	The Determination of Descriptors . . . . .	315
18.3	Applications of the Solvation Equation . . . . .	324
18.3.1	Seiler's $\Delta \log P$ Parameter . . . . .	325
18.3.2	Reversed-phase HPLC . . . . .	326
18.3.3	Water/Micelle Partition . . . . .	327
18.3.4	The Blood-brain Barrier . . . . .	328
18.3.5	Permeation Through Skin . . . . .	331
18.4	Conclusions . . . . .	335
	References . . . . .	335



<b>19</b>	<b>Environmental Hazard Assessment Using Lipophilicity Data</b>	<b>339</b>
	<i>R. L. Lipnick</i>	
19.1	Introduction . . . . .	339
19.2	Historical Perspective . . . . .	340
19.2.1	Nonlinear Relationship to Water Solubility . . . . .	340
19.2.2	Relationship of Toxicity to Chain Length and Molecular Weight . . . . .	340
19.2.3	Chemical Constitution Theory of Hypnotic Activity . . . . .	341
19.2.4	Richet's Law . . . . .	341
19.2.5	Development of the Lipoid Theory of Narcosis . . . . .	341
19.2.6	QSAR and More Quantitative Use of Lipophilicity Data . . . . .	342
19.3	Toxicological Applications . . . . .	342
19.3.1	Contributions of Lazarev . . . . .	342
19.3.2	Development of QSAR in Aquatic Toxicology . . . . .	344
19.3.3	Water Solubility and Pharmacokinetic Cutoff: QSAR Limitations . . . . .	345
19.3.4	Additive Effects of Toxicants . . . . .	345
19.3.5	Bioconcentration . . . . .	346
19.3.6	Thermodynamic Approaches . . . . .	347
19.3.7	Excess Toxicity as a Measure of Specific Mechanism of Action . . . . .	347
19.3.7.1	Electrophile Toxicants . . . . .	348
19.3.7.2	Proelectrophile Toxicants . . . . .	348
19.3.7.3	Cyanogenic Toxicants . . . . .	349
19.4	Biodegradation . . . . .	350
19.5	Outlook . . . . .	350
	References . . . . .	351
<b>20</b>	<b>Lipophilicity in Peptide Chemistry and Peptide Drug Design</b>	<b>355</b>
	<i>J.-L. Fauchère</i>	
20.1	Introduction . . . . .	355
20.2	Lipophilicity of Amino Acids and Parametrization of Side Chain Hydrophobicity . . . . .	356
20.3	Lipophilicity of Peptides, Pseudopeptides and Mimetics . . . . .	358
20.3.1	Experimental <i>P</i> Values for Peptides . . . . .	358
20.3.2	Calculated Values of log <i>P</i> (log <i>D</i> ) for Peptides . . . . .	360
20.3.3	Pseudopeptides . . . . .	362
20.3.4	Peptidomimetics . . . . .	363
20.4	Lipophilicity and Peptide Conformation . . . . .	364
20.4.1	Log <i>P</i> and Conformation . . . . .	364
20.4.3	Amphipathic Secondary Structures . . . . .	365
20.4.4	Hydrophobic Collapse . . . . .	365
20.4.5	Molecular Lipophilicity Potential . . . . .	366
20.5	Lipophilicity and Peptide Transport . . . . .	366
20.5.1	Pharmacokinetic Properties . . . . .	366
20.5.2	Hydrogen Bonding and Hydrophobicity . . . . .	366

20.5.3	Prodrugs . . . . .	368
20.6	Conclusion and Outlook . . . . .	369
	References . . . . .	370
<b>21</b>	<b>Side Chain Lipophilicity of Noncoded <math>\alpha</math>-Amino Acids: <math>\pi</math>-Values . . . . .</b>	<b>375</b>
	<i>V. Pliška and E. Escher</i>	
21.1	Introduction . . . . .	375
21.2	Lipophilicity Descriptor $\pi$ . . . . .	376
21.3	Description of Tables . . . . .	376
21.4	Newly Reported $\pi$ -values . . . . .	377
21.5	Tables . . . . .	378
	References . . . . .	386
<b>22</b>	<b>The Application of the Intermolecular Force Model to Bioactivity, Peptide and Protein Quantitative Structure-Activity Relationships . . . . .</b>	<b>387</b>
	<i>M. Charton</i>	
22.1	Introduction . . . . .	387
22.1.1	The Intermolecular Force (IMF) Equation . . . . .	388
22.1.1.1	Intermolecular Force Parameterization . . . . .	388
22.1.1.2	Steric Effect Parameterization . . . . .	389
22.1.2	The Composition of the Side Chain Effect . . . . .	390
22.1.3	The IMF Equation for Peptide and Protein Bioactivity . . . . .	390
22.2	The IMF Method as a Bioactivity Model . . . . .	390
22.2.1	The Hansch-Fujita Model . . . . .	390
22.2.2	Alternatives to the Use of Lipophilicity Parameters . . . . .	392
22.3	Bioactivity Model . . . . .	392
22.4	Peptide Bioactivities . . . . .	394
22.4.1	Types of Structural Variation in Peptides . . . . .	394
22.4.2	Peptide QSARs . . . . .	395
22.5	Protein Bioactivities . . . . .	397
22.5.1	Types of Protein Bioactivity Data Sets . . . . .	397
22.5.2	Protein QSAR . . . . .	398
22.5.3	Limitation of the Model in Protein QSAR . . . . .	398
	References . . . . .	399
<b>23</b>	<b>Lipophilicity Descriptors for Structure-Property Correlation Studies: Overview of Experimental and Theoretical Methods and a Benchmark of log <math>P</math> Calculations . . . . .</b>	<b>401</b>
	<i>H. van de Waterbeemd and R. Mannhold</i>	
23.1	Introduction . . . . .	402
23.2	Experimental Lipophilicity Scales . . . . .	402

23.2.1	Shake-Flask Partitioning . . . . .	402
23.2.1.1	Solvent/Water Systems . . . . .	402
23.2.1.2	Aqueous Biphasic Systems . . . . .	403
23.2.2	Chromatographic Methods . . . . .	403
23.2.2.1	RP-TLC . . . . .	403
23.2.2.2	RP-HPLC . . . . .	404
23.2.2.3	CPC . . . . .	404
23.2.3	Alternative Experimental Methods . . . . .	404
23.2.3.1	Slow Stirring . . . . .	404
23.2.3.2	Filter Probe and Filter Chamber . . . . .	405
23.2.3.3	Flow-Injection Extraction . . . . .	405
23.2.3.4	Microscale Partitioning Apparatus . . . . .	405
23.2.3.5	pH-Metric log <i>P</i> Determination . . . . .	405
23.3	Calculated log <i>P</i> values . . . . .	405
23.3.1	Overview . . . . .	405
23.3.1.1	The $\pi$ -System . . . . .	405
23.3.2	ALOGP Methods . . . . .	406
23.3.2.1	Calculation Method According to Ghose-Crippen . . . . .	406
23.3.2.2	The HINT Approach of Abraham . . . . .	407
23.3.2.3	The SMILOGP Approach of Dubost . . . . .	407
23.3.3	BLOGP Methods . . . . .	407
23.3.3.1	Conformation-Dependent log <i>P</i> calculations . . . . .	408
23.3.4	CLOGP Methods . . . . .	408
23.3.4.1	The $\Sigma f$ System of Rekker . . . . .	408
23.3.4.2	CLOGP System of Hansch and Leo . . . . .	408
23.3.4.3	Calculation Method According to Suzuki and Kudo . . . . .	409
23.3.4.4	The CASE KLOGP Method . . . . .	409
23.4	Comparison of log <i>P</i> Calculation Methods . . . . .	409
23.4.1	A Benchmark of Simple Organic Compounds and Drugs . . . . .	410
23.4.1.1	General Remarks . . . . .	410
23.4.1.2	The Full Data Set . . . . .	410
23.4.1.3	Subsets: Drugs and Simple Organic Compounds . . . . .	411
23.5	Databases . . . . .	411
23.5.1	Log <i>P</i> Databases . . . . .	411
23.5.2	Substituent Values for Aliphatic and Aromatic Substituents . . . . .	413
23.5.3	Lipophilicity Scales for Amino Acids . . . . .	413
23.6	Perspectives . . . . .	414
	Acknowledgements . . . . .	415
	References . . . . .	415
<b>Index</b>	. . . . .	419

This Page Intentionally Left Blank

# 1 Lipophilicity: The Empirical Tool and the Fundamental Objective. An Introduction

*Vladimir Pliška, Bernard Testa and Han van de Waterbeemd*

## 1.1 Setting the Scene

At the end of the 7th QSAR Symposium held in Interlaken in 1988, the organisers asked a number of participants which topics they felt should require greater attention in future meetings. The list of suggestions was indeed long and diverse. One subject, however, was mentioned almost unanimously, namely the pharmacological, toxicological, and pharmacokinetic significance of weak interactions in general and lipophilicity in particular.

This interest is understandable and legitimate. Weak interactions such as hydrogen bonds, van der Waals forces, hydrophobic effects, and charge transfer interactions are absolutely essential for molecular recognition and interactions in living systems. They underlie the formation of firmly determined molecular and supramolecular structures (for instance in biological macromolecules, membranes, etc.) and, at the same time, enable their amazing flexibility and adaptability. As a rule, several weak forces participate in any interaction occurring in a biological system. Due to their superposition, intermolecular and intramolecular complexes may exhibit a broad range of association constants from about  $10^4 \text{ mol L}^{-1}$  (enzyme-substrate complexes) to  $10^{14} \text{ mol L}^{-1}$  (polyvalent antibody-antigen complexes). Since biologically important macromolecules always contain a variety of polar and nonpolar sites, the role of polar and hydrophobic forces is of utmost significance in all processes of biological recognition.

Before going any further, it appears appropriate to comment on the words “hydrophobicity” and “lipophilicity” since they are used rather loosely and inconsistently in the literature. As discussed in greater details below, lipophilicity is a molecular property expressing the relative affinity of solutes for an aqueous phase and an organic, water-immiscible solvent. As such, lipophilicity encodes most of the intermolecular forces that can take place between a solute and a solvent. In contrast, hydrophobicity is a consequence of attractive forces between nonpolar groups (e.g., hydrocarbon chains and rings) and therefore is but one component of lipophilicity. Factorization of lipophilicity into its polar and hydrophobic components contributes considerably to our understanding of the nature of lipophilicity and its role in the biological world [1, 2].

## 1.2 Biological Aspects

The relation between lipid solubility and biological effects of drugs was recognized almost a century ago by Meyer [3] and by Overton [4]. Some decades later, Pauling discovered a relationship between lipophilicity and anesthetic potency in a series of chem-

ically heterogeneous compounds [5]. It soon became evident that a quantification, or even a description of lipophilicity in thermodynamic terms, is not practicable. Until now, only empirical scales of lipophilicity have been of importance in practice, some expressing the changes in free energy associated with solute transfer between two phases, others being dimensionless indices relating partitioning data of given solutes to a general standard. This latter approach is based on the assumption of linear free-energy changes and is represented by the Leffler-Grunwald operators [6]. It was, in fact, first employed by Hammett in 1935 to describe electronic properties of substituent groups attached to a fixed molecular backbone [7]. Later, Zahradnik and coworkers used responses obtained in two related biological systems to derive what is in fact, but not by name, a set of lipophilicity constants [8, 9]. Such attempts were not unique during the late 1950s and early 1960s. However, it is to the great credit of Hansch, Fujita and Leo that empirical constants can be readily used in pharmacology and toxicology [10, 11]. Besides deriving an extensive set of lipophilicity descriptors, the so-called  $\pi$ -values, Hansch and colleagues proved their apparent additive nature, thus establishing them as genuine substituent constants.

The structure and function of any biological system are closely related to the lipophilic properties of its component molecules. First, lipid-lipid interactions strongly influence the structure of biological membranes, and thereby the compartmentation of compounds within cell organelles. Second, transport and distribution processes within biological systems are to a large extent controlled by the lipophilicity of the system components. The highly hydrophobic interior of a bilayer membrane enables or facilitates the passage of lipophilic substances and prevents the free diffusion of polar molecules except water in and out of cells and organelles. By controlling both transport and compartmentation processes with some degree of selectivity, lipophilicity imposes an adjustable resistance to free diffusion, thus becoming the major obstacle to a random distribution of substances in biological systems, which would be entirely incompatible with life. The same is true for distribution within an organism where several physiological barriers control the access of endogenous and exogenous compounds to various organs and tissues. It is well established that the hemato-encephalic (blood-brain), placental and hemato-mammary (blood-mammary gland) barriers are of a very selective nature, so that specific transporter systems have to mediate the passage of vital compounds, the hydrophilicity of which prevents their passive membrane permeation.

Last, but not least, lipophilicity plays a dominating role in ligand-receptor interactions, e.g., in the binding of hormones, neurotransmitters, modifiers of cellular processes (e.g., growth, initiation, or repression factors) and drugs to their receptors. The same applies for enzyme-substrate, enzyme-inhibitor, antigen-antibody and other ligand-macromolecule interactions.

### 1.3 The Molecule in the Background

While molecular pharmacology deals with the response of a cell to a substance recognized as a message, medicinal chemistry attempts to unveil the semantics, and perhaps also the syntax, of the molecular language which encodes these messages. In order to achieve this, molecular structure has to be described in a pharmacologically relevant

way; adoption of a multilevel description of molecular structure [12] appears to be the best approach to this end. Such a description starts at a simple geometrical level, continues with a stereoelectronic one, and ends up at levels of intermolecular interactions. It is at these latter levels that one encounters properties like solubility and lipophilicity whose high content in structural information remains difficult to understand fully.

Lipophilicity, however, is far from being only an empirical tool in structure-activity analysis. It is also a unique probe that can be used to unravel the complex and dynamic interplay between intermolecular forces and intramolecular interactions in solutes of interest. The former comprise interactions between a solute and the aqueous and organic phases, namely [1, 2, 13]:

- Ion-ion and ion-dipole (permanent, induced) interactions (for ionic solutes);
- Charge transfer interactions;
- Hydrogen bonds (normal, reinforced);
- Van der Waals interactions (forces of orientation, induction, and dispersion);
- Hydrophobic bonds.

Intramolecular interactions that influence lipophilicity can be classified as follows:

- Through-bond electronic effects a) in aromatic systems, and b) across aliphatic segments;
- Through-space electronic/polar effects comprising a) internal electrostatic bonds (ionic bonds, H-bonds, and other electrostatic bonds), b) internal electrostatic repulsion, and c) collision of hydration spheres due to proximity effects between polar groups;
- Through-space steric/hydrophobic effects comprising a) internal hydrophobic bonds (hydrophobic collapse), and b) internal steric hindrance.

Intramolecular interactions can explain differences in lipophilicity seen between regioisomers and between configurational diastereomers. The interplay between conformational diastereomerism and lipophilicity, which is particularly manifest in molecular chameleons, is gaining increasing recognition in compounds of sufficient size and functional complexity [14]. Furthermore, intramolecular interactions affecting lipophilicity represent a major and incompletely understood challenge to the accuracy of current fragmental systems.

## 1.4 Some Pragmatic Aspects

### 1.4.1 Definitions and Symbols

At this point, we should make an explanatory comment concerning the expressions “hydrophobicity” and “lipophilicity”. Their usage is not uniform. Semantically, they seem to stand for the same feature or object, and are therefore frequently considered to be synonymous. In the scientific use, however, their meaning is quite different. The following operational definitions have been suggested by the IUPAC [15, 16]:

- **Hydrophobicity** is the association of nonpolar groups or molecules in an aqueous environment which arises from the tendency of water to exclude nonpolar molecules.

- **Lipophilicity** represents the affinity of a molecule or a moiety for a lipophilic environment. It is commonly measured by its distribution behavior in a biphasic system, either liquid-liquid (e.g., partition coefficient in 1-octanol/water) or solid-liquid (e.g. retention on RP-HPLC or TLC, see section 1.4.2) systems.

Such definitions are by no means unambiguous and noncontroversial, as our knowledge of molecular mechanisms underlying these phenomena, although continuously growing, is still far from being complete. There are, however, pragmatic reasons for their (albeit tentative) differentiation, and it is therefore not astonishing that they occur with different frequency in languages used in different research disciplines. The term “hydrophobicity” is familiar to biophysicists working with X-ray diffraction, NMR spectroscopy and molecular models. It is used in connection with the description of the molecular surface of a compound in contact with an aqueous environment. “Lipophilicity” is a term mainly employed by medicinal chemists to describe transport processes of a compound in biological systems. Much confusion also exists in the symbols of lipophilicity parameters. To bring some clarity, we offer in Table 1 a compilation of useful symbols.

### 1.4.2 Experimental Techniques

A great step forward has been achieved since the pioneering work of Meyer [3] and of Overton on the partitioning of anesthetics in olive oil/water [4]. Hansch, Fujita and their coworkers chose the 1-octanol/water solvent system as an arbitrary standard for expression of lipophilicity [10, 11], and pioneered its measurement by the shake-flask technique. Most of the available data refer to this partitioning system. This standard technique, sometimes laborious and precarious, can efficiently and quite safely be sub-

**Table 1.** Lipophilicity parameters and their recommended symbols

Referred Symbol	Parameter	Alternatives
$\log P$	partition coefficient of neutral species <sup>a</sup>	$\log K$ , $\log PC$
$\log P_{\text{oct}}$	$\log P$ for 1-octanol/water	
$\log P_{\text{alk}}$	$\log P$ for alkane/water	
$\log D$	distribution coefficient: “apparent” partition <sup>a</sup> coefficient	$\log P'$ , $\log P_{\text{app}}$
$\log D_{\text{oct}}$	$\log D$ for 1-octanol/water	
$\log D_{\text{alk}}$	$\log D$ for alkane/water	
$\log P^+$	partition coefficient of cationic form	
$\log P^-$	partition coefficient of anionic form	
$\log P^{+/-}$	partition coefficient of zwitterionic form	
CLOGP	$\log P$ calculated by the CLOGP program <sup>b</sup>	
$\log k$	log of capacity factor in RP-HPLC	
$\log k_w$	$\log k$ extrapolated to 100 % aqueous eluent	

<sup>a)</sup>  $\log P$  and  $\log D$  can be calculated one from the other using the appropriate correction for ionization [1].

<sup>b)</sup> Reference [19].



stituted by various chromatographic techniques: thin-layer chromatography (TLC), reversed-phase high performance liquid chromatography (RP-HPLC or RPLC), and centrifugal partition chromatography (CPC), which are all employed routinely.

### 1.4.3 Computational Procedures

Lipophilicity has been expressed by means of manifold descriptors mainly based on partition coefficients or similar thermodynamic features. Relationships between individual scales are, apart from some exceptions, very close. These descriptors can be obtained by a number of computational routines; they receive attention in this book. Fragmental constants, i.e., contributions of individual molecular fragments to the overall value of a descriptor, are roughly additive and thus afford quick predictions of lipophilicity from molecular structures. In this way, some problems and limitations associated with the experimental assessment of substituent constants can be overcome [17]. From a visual point of view, this property has been simulated as a dynamic process, exhibiting the characteristics observed experimentally [18].

From a practical point of view, lipophilicity descriptors are important for at least two reasons. First, they may predict unsatisfactory drug candidates and avoid, in a simple way, an extensive experimentation. This relates to both transport properties and intrinsic activity of the potentially interesting substances. Second, they enable to investigate structure-property relationships, in particular intermolecular forces and intramolecular interactions. These relationships are of utmost importance in drug design. It would be, for example, of little use to design a highly hydrophilic substance if it is targeted to the central nervous system.

## 1.5 Objectives of the Book

In summary, lipophilicity is an essential property of molecules whose roles in biological systems are numerous and essential. Above all, it is intimately connected with regulatory pathways in living systems, and allows them to exist away from equilibrium. In so far as medicinal chemists and pharmacologists aim at sending messages (i.e., drugs) to ailing cells, they cannot avoid viewing lipophilicity as one of the most significant properties controlling both the delivery and the reception of the message.

The aim of this monograph is therefore rather straightforward, namely, to present the state-of-the-art of the area, to bring about a current insight necessary for interpretation of lipophilicity data, and to demonstrate how research in cell biology, pharmacology, medicinal chemistry, toxicology, and related fields can benefit from them. Our main interest, however, is to put emphasis on lipophilicity as an important property controlling a great many processes in living organisms.

## References

- [1] van de Waterbeemd, H., and Testa, B., *Adv. Drug Res.* **16**, 85–225 (1987)
- [2] El Tayar, N., Testa, B. and Carrupt, P. A., *J. Phys. Chem.* **96**, 1455–1459 (1992)
- [3] Meyer, H., *Arch. Exp. Pathol. Pharmacol.* **42**, 109–118 (1899)
- [4] Overton, E., *Studien über die Narkose*. Fisher: Jena 1901
- [5] Pauling, L., *Science* **139**, 15–21 (1961)
- [6] Leffler, J. E., and Grunwald, E., *Rates and Equilibria of Organic Reactions, As Treated by Statistical, Thermodynamic and Extrathermodynamic Method* Wiley: New York 1963, p. 22–27
- [7] Hammett, L. P., *Chem. Rev.* **17**, 125–136 (1935)
- [8] Zahradnik, R. and Chvapil, M., *Experientia*, **16**, 511–512 (1960)
- [9] Zahradnik, R., *Arch. Int. Pharmacodyn.* **85**, 311–329 (1962)
- [10] Hansch, C., and Fujita, T., *J. Am. Chem. Soc.* **86**, 1616–1626 (1964)
- [11] Hansch, C., and Leo, A., *Substituent Constants for Correlation Analysis in Chemistry and Biology*. Wiley: New York 1979
- [12] Testa, B., and Kier, L. B., *Med. Res. Rev.* **11**, 35–48 (1991)
- [13] El Tayar, N., Tsai, R. S., Testa, B., Carrupt, P. A., and Leo, A., *J. Pharm. Sci.* **80**, 590–598 (1991)
- [14] Carrupt, P. A., Testa, B., Bechalany, A., El Tayar, N., Descas, P. and Perrissoud, D., *J. Med. Chem.* **34**, 1272–1275 (1991)
- [15] *Glossary of Terms Used in Medicinal Chemistry*, IUPAC, in press
- [16] *Glossary of Terms Used in Computational Drug Design*, IUPAC, in press
- [17] Rekker, R. F., *The Hydrophobic Fragmental Constant. Its Derivation and Applications. A Means of Characterizing Membrane Systems*. Elsevier: Amsterdam 1977
- [18] Kier, L. B., Chen, C.-K., Testa, B., and Carrupt, P.-A., *Pharmaceut. Res.* **12**, 1–6 (1995)
- [19] Leo, A. J., *Chem. Revs.* **93**, 1281–1306 (1993)

# 2 Lipophilicity: A History

*Michael S. Tute*

## Abbreviations

AM1	Molecular orbital program (Dewar)
CLOGP	Program for lipophilicity calculation
HPLC	High performance liquid chromatography
HYDRO	Program for lipophilicity calculation on flexible solutes
ISA	Isotropic (non-polar) surface area
SASA	Solvent accessible surface area
SCAP	Program for lipophilicity calculation using solvent-dependent conformations
TLC	Thin layer chromatography

## Symbols

$D$	Distribution coefficient
$f$	Hydrophobic fragmental constant
$P$	Partition coefficient, refers usually to octanol/water
$S$	Molar solubility
$S_A$	Surface area
$S_i$	Atomic surface area
$T_m$	Melting point
$V$	Solute volume
$\alpha_H$	Solute H-bond donor strength
$\beta_H$	Solute H-bond acceptor strength
$\Delta q_i$	Atomic partial charge
$\pi$	Hydrophobic substituent constant
$\pi^*$	Solute polarity/polarisability
$\pi_H$	Enthalpic component of hydrophobic substituent constant
$\pi_s$	Entropic component of hydrophobic substituent constant
$\sigma$	Hammett electronic substituent constant

## 2.1 Introduction

Lipophilicity is usually expressed by the partition coefficient ( $\log P$ ), a molecular parameter which describes the partitioning equilibrium of a solute molecule between water and an immiscible lipid-like organic solvent. By convention, the ratio of concentrations in the two phases is given with the organic phase as numerator, so that a positive value for  $\log P$  reflects a preference for the lipid phase, and a negative value reflects a

relative affinity for water. Also by convention, where ionizable molecules are concerned,  $\log P$  refers to the neutral species whereas what is actually measured may be the distribution coefficient,  $\log D$ . The distribution coefficient refers to the ratio of total concentrations of ionized and unionized species across both phases.

Many workers have emphasized that the value of  $\log P$  depends largely on interactions made by the solute with the water phase, either being repelled by water (hydrophobic effect) or solvated by water through hydrogen bonds or other polar forces (hydrophilic effect). Such emphasis has encouraged use of the term hydrophobicity, and in medicinal chemistry and particularly for QSAR the substituent constants,  $\pi$ , and fragment constants,  $f$ , are almost universally described as hydrophobic substituent parameters or hydrophobic fragmental constants.

Use of the term hydrophobicity has also been dependent on a perception of the thermodynamics of partitioning of strictly nonpolar solutes such as the aliphatic and aromatic hydrocarbons between water and a lipid phase, and on a particular use of the term “hydrophobic bonding” to describe the tendency of nonpolar groups to associate in aqueous solution, thereby reducing the extent of contact with neighboring water molecules. As discussed by Némethy [1], the formation of such “hydrophobic bonds” has long been considered to be driven by an entropy effect: the water molecules become more ordered around exposed nonpolar residues, and when the hydrophobic “bond” is formed, the order decreases, resulting in a favorable entropy and hence free energy of formation. For over 30 years, it has been commonly supposed that the “hydrophobic” interaction between nonpolar side chains of a protein, associated with formation and breakdown of layers of abnormal water, makes a prominent contribution to the stability of the native, folded form. The existence, nature, and effect of “hydrophobic hydration” is today a subject of intense controversy (see section 2.4.2).

Use of the term hydrophobicity by the Hansch group [2], who in 1964 pioneered the use of octanol/water as the standard solvent pair for measurement, could also be justified on the grounds that this particular solvent pair is such that polar effects are similar in each phase. Both water and octanol have hydroxyl groups that can participate in polar interactions with the solute molecule, and moreover there is a considerable amount of water within the octanol phase. So, an octanol/water  $\log P$  value will emphasize differences in hydrocarbon interactions with water and with lipid, but tend to hide differences in the interaction of polar and hydrogen-bonding groups.

Recent studies have clearly and repeatedly shown that  $\log P$  in general incorporates two major contributions, namely a “bulk” term reflecting both hydrophobic (entropic) and dispersion (enthalpic) effects, and electrostatic terms reflecting hydrogen bonds and other dipole-dipole effects. Moreover, the emphasis on interaction of the solute with the water phase has been challenged; more emphasis has now been placed on enthalpic interactions within the lipid phase; free energy simulations have been carried out and thermodynamic measurements have been made to better understand fundamental interactions of the solute with each phase. As a result, traditional explanations of partitioning in terms of “hydrophobic bonding” have had to be reconsidered.


## 2.2 Measurement of Lipophilicity

The partition coefficient was first defined in 1872 by Berthelot and Jungfleisch [3], who wrote "*On the Laws that Operate for the Partition of a Substance between two Solvents*". It was first used to correlate and explain the potencies of biologically active substances at the turn of the century, by both Meyer [4] and Overton [5] in their studies of narcotic compounds. Overton's work stimulated other investigations of the use of partition coefficients for biological correlations, among them a study by Seidell [6] in 1912. Believing that the partition coefficient of thymol might be relevant to a study of the mode of action of thymol against hookworm, Seidell made measurements using a variety of lipid phases, including olive oil, castor oil, peanut oil, and linseed oil. In those days, measurement was particularly tedious: it was necessary to separate thymol from the oil by a steam distillation, and then to estimate thymol in water by treatment with bromine, titrating the resulting hydrobromic acid produced!

With the development of UV spectroscopy, measurement of the partition coefficient for compounds with strong absorption, nonextreme values, and sufficient solubility in the aqueous phase has become routine, using the "shake-flask" method, partitioning between one of a wide variety of lipid phases, and water or an appropriate buffer solution as the aqueous phase. For many ionizable compounds, compounds of low solubility, and compounds with low UV absorbance or extreme values of partition coefficient then special methods of measurement or alternative lipophilicity parameters have had to be devised.

In 1959, Gaudette and Brodie [7] realized both the possibility for using a partition coefficient to model lipophilic character, and the relevance of lipophilicity to pharmacokinetic processes. They found a parallel between the heptane/buffer partition coefficients of certain drugs, and their rate of entry into cerebrospinal fluid. However, generalised use of  $\log P$  as a lipophilicity parameter did not come about until after 1964, with the Hansch octanol/water system remaining to this day the standard for both experimental and theoretical investigations. In 1971, Leo, Hansch and Elkins [8] published the first comprehensive review of partition coefficients, with a tabulation of nearly 6000 values, including their own measurements on some 800 in the octanol/water system. The review incorporated an account of the shake-flask method of measurement, which was discussed more exhaustively in a 1973 monograph by Purcell, Bass and Clayton [9].

Octanol/water  $\log P$  has also been measured by high-performance liquid chromatography [10], and by using a filter-probe to sample selectively from the aqueous or lipid phase so there is no need to fully separate the phases [11, 12]. For ionizable compounds, Brandström in 1963 [13] was first to use a potentiometric titration technique. One aqueous phase titration, with a pH-meter probe, was carried out in the aqueous phase to determine  $pK_a$ . A second titration was carried out in the presence of octanol, when partition occurred and the  $pK_a$  shifted. The difference in  $pK_a$  was related to  $\log P$ . In 1974 Seiler [14] modified this technique so as to determine  $pK_a$  and  $\log P$  from a single titration. The technique has now been refined to enable not only simultaneous  $pK_a$  and  $\log P$  determination, but to allow treatment of substances with multiple ionization constants, ion-pair partitioning, and self-association reactions leading to the formation of oligomers [15, 16].



**Figure 1.** Structural similarities between propylene glycol dipelargonate (PGDP) and a phospholipid molecule.

Lipophilicity has, since 1964, been traditionally measured in the octanol/water system. However, for particular purposes and for particular sets of compounds, other solvent pairs have been used. Octanol/water values have been shown to be generally satisfactory for modeling serum protein binding and for modeling lipophilic interactions with biological membranes consisting largely of protein, but for other types of membrane then a different solvent system might be more appropriate. In 1989, Leahy et al. [17] suggested that membranes (or receptors) could exist with very different hydrogen bonding characteristics from those of octanol. Thus, membranes may contain neither acceptors nor donors (modeled by an alkane); or contain largely amphiprotic groups (as in a protein, modeled by octanol); largely proton donor groups (which may be modeled by chloroform); or largely proton acceptor groups (as in a phospholipid membrane). Leahy argued for the use of propylene glycol dipelargonate (PGDP) as lipid phase to model phospholipid membranes (Fig. 1) and have accordingly measured many partition coefficients in the PGDP/water system [18].

For many compounds, the traditional equilibrium method of partition coefficient measurement may be impossible, impractical, or inappropriate. As a practical alternative to  $\log P$ , particularly for biological correlations, much use has been made of parameters derived from chromatographic retention. In 1941 Martin and Synge [19] showed that for reversed phase thin-layer chromatography, Eq. (1) relates partition coefficient,  $P$ , to the ratio,  $R_f$ , of distances moved by the compound spot and the solvent front in a given time, with  $K$  being a constant for the system. In 1950 Bate-Smith and Westall [20] defined the parameter  $R_m$  as in Eq. (2) from which Eq. (3) follows. In practice, excellent correlations have been found between  $R_m$  and  $\log P$  taking the form of Eq. (4). Kaliszan [21] has reviewed the use of lipophilicity parameters derived from HPLC, TLC, and paper chromatography.

$$P = K \left[ \left( \frac{1}{R_f} \right) - 1 \right] \quad (1)$$

$$R_m = \log \left[ \left( \frac{1}{R_f} \right) - 1 \right] \quad (2)$$

$$R_m = \log P - \log K \quad (3)$$

$$R_m = a \log P + b \quad (4)$$

## 2.3 Calculation of Lipophilicity

### 2.3.1 Substitution Method

The Hansch group were the first to point out [2] in their influential paper of 1964, that the octanol/water  $\log P$  value of simple benzenoid derivatives could be calculated by a method bearing close analogy to the Hammett [22] treatment of chemical reactivity, including ionization, of substituted benzene derivatives. Hammett had shown in the 1930s that the equilibrium or rate constant of parent (unsubstituted) molecule,  $K_H$ , and the equilibrium or rate constant for a substituted compound,  $K_X$ , could be correlated by

$$\log \left( \frac{K_X}{K_H} \right) = \rho \sigma_X \quad (5)$$

which could be rewritten as

$$\log K = \rho \sigma_X + \log K_H \quad (6)$$

The substituent constant  $\sigma_X$  refers to the electronic effect of the substituent and is a parameter applicable to many different reactions (characterized by different values of  $\rho$ ) whose rate depends on the degree of electron release or withdrawal by the substituent. For the derivation of  $\sigma$  constants, the ionization of benzoic acids was defined as the standard reaction for which  $\rho$  was set to unity. In analogous fashion to the Hammett treatment, Hansch defined substituent constants,  $\pi$ , by Eq. (7), choosing octanol/water as the standard system. Then, by analogy to Eq. (6) for reaction rates or equilibria, Eq. (8) could be used to calculate  $\log P$ .

$$\log \left( \frac{P_X}{P_H} \right) = \pi_X \quad (7)$$

$$\log P_X = \log P_H + \pi_X \quad (8)$$

Just as Hammett had found that different  $\sigma$  values were required for para- and for meta-substituents on a benzoic acid, because of differing contributions of field and resonance effects on reactivity, so the Hansch group immediately recognized that different  $\pi$  values would be required according to the environment of the substituent. Electronic effects in particular would alter the interaction of a polar substituent with the water phase: consider 4-nitrophenol, where neither the hydroxyl group nor the nitro group would behave towards water or towards octanol in like fashion to the hydroxyl or nitro group in phenol itself, or in nitrobenzene. It was rapidly appreciated that the lipophilicity parameter,  $\log P$ , was only to a first approximation an additive property: it has considerable constitutive character. This at first proved to be a major difficulty for the calculation of lipophilicity, but in fact opened the way to using lipophilicity measurements to probe a variety of intramolecular effects, including not only electronic but steric effects, so-called proximity effects when polar groups share a solvation shell, hydrogen bonding, and conformation (sometimes called folding effects, see chapter 4).

### 2.3.2 Fragment Additivity Method

The  $\pi$ -system was used for some 15 years, but was destined to give way to a much more general fragmentation method of calculating  $\log P$ . The substituent scheme was only applicable, in general, to substituted benzene derivatives. For other compounds, the problem immediately arose, what does one take as “parent” and what as substituent? Moreover, rather serious errors occurred in the application and interpretation of lipophilicity calculations using the substituent approach. Hansch and Anderson [23] in 1967 suggested that the difference in calculated  $\log P$  and in measured  $\log P$  (which was lower) in compounds of the type  $C_6H_5CH_2CH_2CH_2X$  indicated a folding of the alkyl chain, so that substituent X interacted with the aromatic ring through “intramolecular hydrophobic bonding”. In 1973 Nys and Rekker [24] suggested that the difference did not arise from any intramolecular folding, but in fact arose because of the implicit neglect of the lipophilicity of hydrogen. The application of Eq. (7) to calculate  $\log P$  for the compounds above requires the addition:

$$\log P(C_6H_5 - CH_2 - CH_2 - CH_2 - X) = \log P(C_6H_5) + 3\pi(CH_3) + \pi(X)$$

and makes no distinction between the lipophilicity of  $CH_3$  or  $CH_2$ .

Nys and Rekker [24, 25] then suggested a totally different approach to  $\log P$  calculation, which was to transform our understanding. This approach was based on the assignment of “fragmental constants”,  $f$ , to a selection of structural fragments, the calculated  $\log P$  then being simply the sum of fragment values appropriate to the molecule plus a number of interaction factors,  $F$ , that were necessary to correct for intramolecular electronic or steric interactions between fragments. The fragment system is expressed by Eq. (9):

$$\log P = \sum_{i=1}^m f_i + \sum_{i=1}^n F_i \quad (9)$$

Rekker used a large database of published  $\log P$  values to derive both fragment values and correction factors statistically. His first book on the method was published in 1977 [26] and refinements were later made by Rekker and de Kort in 1979 [27] using a database of over one thousand  $\log P$  measurements. A second book in 1992 by Rekker and Mannhold [28] includes further refinements and example calculations.

A feature of Rekker-type calculations as currently implemented is that many of the correction factors,  $F$ , are considered to be multiples of a so-called “magic constant”,  $C_M$ , the latest value for which is 0.219 [28]. The calculation of lipophilicity therefore follows Eq. (10) with, for example, a proximity correction of  $kn$  (key number) equal to 2 for a two-carbon separation of polar groups:

$$\log P = \sum_{i=1}^m f_i + \sum kn.C_M \quad (10)$$

There has been much speculation as to whether the “magic constant” has any fundamental significance, Rekker having proposed that it might be related to a quantum displacement of water in the first solvation shell around the solute.